Avidity heads to FDA with exon 44 skipping Duchenne muscular dystrophy drug

Avidity Biosciences shared Monday that its RNA drug for people with certain mutations of Duchenne muscular dystrophy continued to show strong results as it completed a Phase 1/2 study, and the biotech is planning to ...